ahmed group lecture 15 cancer lecture 15 ahmed group lecture 15 cancer as a genetic disease...
TRANSCRIPT
Ahmed GroupAhmed GroupLecture 15Lecture 15
CANCER
LECTURE 15
Ahmed GroupAhmed GroupLecture 15Lecture 15
• Cancer as a Genetic Disease• Oncogenes• Tumor suppressor genes• Telomeric changes in cancer• Epigenetic changes in cancer: e.g. hypermethylation• Multi-step nature of carcinogenesis• Repair genes in carcinogenesis• The processes of metastasis• Molecular profiling and staging of cancer: Gene
expression profiling and proteomics• Signaling abnormalities in cancer: Effects of signaling abnormalities on radiation responses• Prognostic significance of tumor characteristics• Therapeutic targets and strategies for intervention• Monoclonals, small molecule inhibitors, gene therapy
Cancer
Ahmed GroupAhmed GroupLecture 15Lecture 15
Gain if function mutation in an
oncogene
Loss of function mutation in a tumor
suppressor gene
Malignant Transformation
The process of malignant transformation may result from either a gain-of-function mutation that activates an oncogene, or a loss-of-function mutuation in a tumor-suppressor gene.
Cancer as a Genetic Disease
Neoplastic Development
Ahmed GroupAhmed GroupLecture 15Lecture 15
The way in which the concept of oncogenes provides a ready answer for how agents as diverse as viruses, radiations, and chemicals all can induce tumors that are essentially indistinguishable from another. The retrovirus inserts a gene; a chemical may activate an endogenous oncogene by a point mutation; radiation may do the same by, for example a translocation.
Augmented Expression
Normal Expression
Inappropriate Expression
Neoplastic Growth
Normal Growth & Development
Radiation (Translocation)
Chemicals (Point Mutation)Retrovirus
inserts gene
Activated oncogene
Ahmed GroupAhmed GroupLecture 15Lecture 15
• Cancer as a Genetic Disease• Oncogenes• Tumor suppressor genes• Telomeric changes in cancer• Epigenetic changes in cancer: e.g. hypermethylation• Multi-step nature of carcinogenesis• Repair genes in carcinogenesis• The processes of metastasis• Molecular profiling and staging of cancer: Gene
expression profiling and proteomics• Signaling abnormalities in cancer: Effects of signaling abnormalities on radiation responses• Prognostic significance of tumor characteristics• Therapeutic targets and strategies for intervention• Monoclonals, small molecule inhibitors, gene therapy
Cancer
A gene that causes cancer is called an oncogene
Humans contain genes that can be converted to oncogenes
A normal gene with the potential to become an oncogene is called a proto-oncogene
Many proto-oncogenes code for growth factors.
Oncogenes were first discovered from study of retroviruses.
There are two types of Tumor Viruses
DNA Tumor viruses.
RNA Tumor viruses.
ONCOGENE
Conversion of a protooncogene into an oncogene
Deletion or point mutation in coding sequence
Gene amplificationChromosome rearrangement
Hyperactive protein made in normal amounts
Normal protein greatly overproduced
Near strong enhancer overexpression of normal protein
Fusion protein is hyperactive
Protooncogene to Oncogene
1. A point mutation, eg., K-Ras2. Chromosomal rearrangement3. Gene AmplificationChronic Myelogenous Lymphoma
Burkitt’s Lymphoma
Between 8 and 14
Acute myelocytic leukemia7:15, 9:18, 11:15:17
Myc gene has IgG Promoter
Protooncogene to Oncogene
1. A point mutation2. Chromosomal rearrangement3. Gene Amplification
N-myc is a characteristic ofmany neuroblastomas
+
+
+
-
+
+
Myc
Ahmed GroupAhmed GroupLecture 15Lecture 15
Cooperating genes
Ahmed GroupAhmed GroupLecture 15Lecture 15
Chromosomal Changes Leading to Oncogene Activation and the Human Malignancies Associated With Them
Ahmed GroupAhmed GroupLecture 15Lecture 15
• Cancer as a Genetic Disease• Oncogenes• Tumor suppressor genes• Telomeric changes in cancer• Epigenetic changes in cancer: e.g. hypermethylation• Multi-step nature of carcinogenesis• Repair genes in carcinogenesis• The processes of metastasis• Molecular profiling and staging of cancer: Gene
expression profiling and proteomics• Signaling abnormalities in cancer: Effects of signaling abnormalities on radiation responses• Prognostic significance of tumor characteristics• Therapeutic targets and strategies for intervention• Monoclonals, small molecule inhibitors, gene therapy
Cancer
Ahmed GroupAhmed GroupLecture 15Lecture 15
How hybrid cells can be used to demonstrate the way in which tumorigenicity may result from the loss of a suppressor gene. HeLa cells are tumorigenic; normal human fibroblasts are not. HeLa cells are transformed, as indicated by their ability to grow in soft agar, and tumorigenic, as evidenced by their ability to form tumors in immune-suppressed animals. Normal human fibroblasts do not show either property of malignancy. A hybrid formed by the fusion of a HeLa cell and a normal human fibroblast grows in soft agar but does nor form tumors: The malignancy. A hybrid formed by the fusion of a HeLa cell and a normal human fibroblast grows in soft agar but does not form tumors: The malignant phenotype of the HeLa cell is suppressed by the normal fibroblast. If, however, chromosome 11 from the normal fibroblast is lost, tumorigencity is restored, ingene is located on that chromosome.
Tumor-suppressor genes
It was discovered in the 1970s that the tumorigenicity of some tumor cells could be suppressed by hybridization with normal cells
Ahmed GroupAhmed GroupLecture 15Lecture 15
Effects of Suppressor
Illustrating the effect of the suppressor gene on human chromosome 11. HeLa cells are tumorigenic in nude mice. If a microcell is introduced containing chromosome 11 from a mormal human fibroblast, the malignant phenotype of the HeLa cell is suppressed. If durig culture, chromosome 11 is lost, tumorigenicity is restored. The chromosome in the microcell is number 11 translocated with part of the X chromosome containing the HGPRT gene as a marker of the presence or absence of the chromosome in the HeLa cell.
Ahmed GroupAhmed GroupLecture 15Lecture 15
Rb Mutations
Rb mutations in familial and sporadic retinoblastoma. In familial retinoblastoma, one normal and one mutated Rb are inherited (1) Subsequent mutation in any retinal cell inactivates the remaining Rb (2), leading to loss of growth control in a clone of tumor cells (3). In sporadic retinoblastoma, two normal Rb are inherited (4). First, a mutation inactivates one copy of Rb (5). A subsequent mutation within the same retinal cell inactivates the remaining copy of Rb (6), leading to loss of growth control in a clone of tumor cells.
Ahmed GroupAhmed GroupLecture 15Lecture 15
Currently Identified Tumor Suppressor Genes
Ahmed GroupAhmed GroupLecture 15Lecture 15
Gain of function mutation in an
oncogene
Loss of function mutation in a tumor
suppressor gene
AutosomalDominant
Recessiveat the
cellular level
Dominant in a
pedigree
Gain-of-function mutations that result in the activation of an oncogene require only one copy to be activated; that is, oncogenes act in a dominant fashion. Loss-of-function mutations that inactivate a tumor-suppressor gene require both copies to be inactivated for the malignant phenotype to be expressed; that is, tumor-suppressor genes act in a recessive fashion. This may be true at a cellular level; however, in viewing the pedigree of a cancer-prone family, the loss of a tumor-suppressor gene may appear to be inherited as a dominant mutation.
Mutations required for the oncogenes and tumor-suppressor genes to be expressed
Ahmed GroupAhmed GroupLecture 15Lecture 15
Somatic Homozygosity
The process of somatic homozygosity. In a normal cell, ther are two copies of each chromosome. One inherited from each parent. For a given suppressor gene to be ina ctivated, the copy must be lost from both chromosomes. This could, of course, occur by independent deletions from the two chromosomes, but in practice it is more common fro a single deletion to occur in one chromosome while the second chromosome is lost completely. The remaining chromosome, with the deletion, then replicates. The cell is thus homozygous, rather than heterozygous, for that chromosome.
Ahmed GroupAhmed GroupLecture 15Lecture 15
• Cancer as a Genetic Disease• Oncogenes• Tumor suppressor genes• Telomeric changes in cancer• Epigenetic changes in cancer: e.g. hypermethylation• Multi-step nature of carcinogenesis• Repair genes in carcinogenesis• The processes of metastasis• Molecular profiling and staging of cancer: Gene
expression profiling and proteomics• Signaling abnormalities in cancer: Effects of signaling abnormalities on radiation responses• Prognostic significance of tumor characteristics• Therapeutic targets and strategies for intervention• Monoclonals, small molecule inhibitors, gene therapy
Cancer
Ahmed GroupAhmed GroupLecture 15Lecture 15
Telomeres and Cancer
Telomeres cap and protect the ends of chromosomes.Mammalian telomeres consist of long arrays of the repeat sequenceTTAGGG that range in length anywhere from 1.5 to 150 kilobasesEach time a normal somatic cell divides, the terminal end of thetelomere is lost. Telomere length has been described asthe “molecular clock”, because it shortens with age.Cancer cells avoid this process of aging by activating the enzymetelomerase.However, the tumors have been identified with stable telomerelength but undetectable telomerase activity.The questions thus remains: Is immortalization or carcinogenesisintimately associated with telomerase expression or not?
Telomeres and Cell Senescence
Ahmed GroupAhmed GroupLecture 15Lecture 15
• Cancer as a Genetic Disease• Oncogenes• Tumor suppressor genes• Telomeric changes in cancer• Epigenetic changes in cancer: e.g. hypermethylation• Multi-step nature of carcinogenesis• Repair genes in carcinogenesis• The processes of metastasis• Molecular profiling and staging of cancer: Gene
expression profiling and proteomics• Signaling abnormalities in cancer: Effects of signaling abnormalities on radiation responses• Prognostic significance of tumor characteristics• Therapeutic targets and strategies for intervention• Monoclonals, small molecule inhibitors, gene therapy
Cancer
Ahmed GroupAhmed GroupLecture 15Lecture 15
At the outset, it is important that the term epigenetics be defined. Although this term had been coined before, Holliday provided definition for this concept in reviews 15 years or so ago. As used today, this term refers to a change in gene expression that is heritable (ie, that is can be passed on through cell division) but that does not involve a change in DNA sequence.
This contrasts with a true genetic alteration. In this context, it is helpful to look at the entire repertoire of changes that accomplish the gains or losses of gene function that result in the transformed phenotype. These changes are outlined in the next slide and span from those that are completely permanent to those that are very dynamic. Epigenetic changes are semi-permanent.
Epigenetic changes in cancer
Ahmed GroupAhmed GroupLecture 15Lecture 15
Epigenetic changes in cancer
Ahmed GroupAhmed GroupLecture 15Lecture 15
• Genetic alterations are a hallmark of human cancer. • Changes in DNA methylation, an epigenetic modification that is present in
mammalian cells, are also characteristic of human cancer.
• The CpG dinucleotide, which is usually underrepresented in the genome, is clustered in the promoter regions of some genes.
• These promoter regions have been termed CpG islands. CpG islands are protected from methylation in normal cells, with the exception of genes on the inactive X chromosome and imprinted genes.
• This protection is critical, since the methylation of promoter region CpG islands is associated with a loss of expression of these genes.
• The following three different alterations in DNA methylation are common in human cancer: (1) global hypomethylation, often seen within the body of genes; (2) dysregulation of DNA methyltransferase I, the enzyme involved in maintaining methylation patterns, andpotentially other methyltransferases; and (3) regional hypermethylation in normally ummethylated CpG islands.
Epigenetic changes in cancer: e.g. methylation
Ahmed GroupAhmed GroupLecture 15Lecture 15
Epigenetic changes in cancer: e.g. methylation
Ahmed GroupAhmed GroupLecture 15Lecture 15
• Cancer as a Genetic Disease• Oncogenes• Tumor suppressor genes• Telomeric changes in cancer• Epigenetic changes in cancer: e.g. hypermethylation• Multi-step nature of carcinogenesis• Repair genes in carcinogenesis• The processes of metastasis• Molecular profiling and staging of cancer: Gene
expression profiling and proteomics• Signaling abnormalities in cancer: Effects of signaling abnormalities on radiation responses• Prognostic significance of tumor characteristics• Therapeutic targets and strategies for intervention• Monoclonals, small molecule inhibitors, gene therapy
Cancer
Ahmed GroupAhmed GroupLecture 15Lecture 15
Illustrating the multistep nature of carcinogenesis and the concept of the phenotype. The first step in carcinogenesis by radiation or any other agent may be a mutation in one of the gene families responsible for the stability of the genome. This may be a DNA repair gene, a mismatch repair gene, or a gene in a family as yet unidentified. This leads to the mutator phenotype, with multiple mutations possible in both oncogenesand tumor-suppressor genes. This leads to a series of steps that result in an invasive metastatic cancer. Not all the same mutations need to be present in every case.
Multistep Process Of Cancer
Mechanisms of Multistep
Tumorigenesis
Ahmed GroupAhmed GroupLecture 15Lecture 15
Multistep Process Of Cancer
Cancer has long been thought to be a multistep process and has been described with operational terms such as initiation, promotion, and progression. In at least one human malignancy, namely, colon cancer, the molecular events during the progress of the disease have been identified. (Based on the work of Vogelstein)
Hallmarks of Cancer Cells
Self-maintained replicationLonger survivalGenetic instabilityCapable of inducing
neo-angiogenesisCapable of invasion and metastasis
Ahmed GroupAhmed GroupLecture 15Lecture 15
Radiation Carcinogenesis
• A stochastic late effect.• No threshold, an all or none effect.• Severity is not dose related.• Probability of carcinogenesis is dose dependent.• Leukemia has the shortest latency period of ~5 years.
Solid tumors have a latency period of ~20 to 30 years.• Total cancer risk for whole body irradiation is one
death per 104 individuals exposed to 1 rem.• For every leukemia induced there are 3 to 4 sarcoma
induced in the same irradiated population.
Ahmed GroupAhmed GroupLecture 15Lecture 15
• Cancer as a Genetic Disease• Oncogenes• Tumor suppressor genes• Telomeric changes in cancer• Epigenetic changes in cancer: e.g. hypermethylation• Multi-step nature of carcinogenesis• Repair genes in carcinogenesis• The processes of metastasis• Molecular profiling and staging of cancer: Gene
expression profiling and proteomics• Signaling abnormalities in cancer: Effects of signaling abnormalities on radiation responses• Prognostic significance of tumor characteristics• Therapeutic targets and strategies for intervention• Monoclonals, small molecule inhibitors, gene therapy
Cancer
DNA Repair
Oncogenes
Activation
Tumor Suppressor Genes
Inactivation
Differentiation Apoptosis/Proliferation
CANCER
Alterations of Specific Cellular Functions in Alterations of Specific Cellular Functions in CancerCancer
Ahmed GroupAhmed GroupLecture 15Lecture 15
Ahmed GroupAhmed GroupLecture 15Lecture 15
Ahmed GroupAhmed GroupLecture 15Lecture 15
Human Mismatch Repair Genes
Gene Chromosomal location
Germline Mutations in HNPCC Cases (Reported family
Studies), %
hMSH2 2p21-22 (2p16?) 60
hMLH1 3p21 30
hPMS1 2q31-33 4
hPMS2 7p21 4
GTBP 2p16 (2p21-22)?) 0
Repair genes in carcinogenesis
Ahmed GroupAhmed GroupLecture 15Lecture 15
• Cancer as a Genetic Disease• Oncogenes• Tumor suppressor genes• Telomeric changes in cancer• Epigenetic changes in cancer: e.g. hypermethylation• Multi-step nature of carcinogenesis• Repair genes in carcinogenesis• The processes of metastasis• Molecular profiling and staging of cancer: Gene
expression profiling and proteomics• Signaling abnormalities in cancer: Effects of signaling abnormalities on radiation responses• Prognostic significance of tumor characteristics• Therapeutic targets and strategies for intervention• Monoclonals, small molecule inhibitors, gene therapy
Cancer
Ahmed GroupAhmed GroupLecture 15Lecture 15
The processes of metastasis
Cancer cells breaking away from their original site and spread to other parts of the body. The cells spread through blood stream and lymphatic system.
Tumors of the same histologic type arising in different patients differ widely in growth rate. By contrast, metastases arising in the same patient tend to have similar rates of growth. The latter observation is the basis for using patients with multiple skin orpulmonary metastases to test and compare new treatment modalities, such as high linear energy transfer radiations or hyperthermia.
Ahmed GroupAhmed GroupLecture 15Lecture 15
The processes of metastasisData have been accumulated comparing the growth rate of primary breast and bronchial cancers to that of metastases in the same person. The primary carcinomas grew significantly more slowly than the metastases. No entirely satisfactory explanation has been suggested for the more rapid proliferation of metastases. It may be a question of selection or a function of the favorable milieu into which secondary tumors tend to be seeded.
Ahmed GroupAhmed GroupLecture 15Lecture 15
• Cancer as a Genetic Disease• Oncogenes• Tumor suppressor genes• Telomeric changes in cancer• Epigenetic changes in cancer: e.g. hypermethylation• Multi-step nature of carcinogenesis• Repair genes in carcinogenesis• The processes of metastasis• Molecular profiling and staging of cancer: Gene
expression profiling and proteomics• Signaling abnormalities in cancer: Effects of signaling abnormalities on radiation responses• Prognostic significance of tumor characteristics• Therapeutic targets and strategies for intervention• Monoclonals, small molecule inhibitors, gene therapy
Cancer
Ahmed GroupAhmed GroupLecture 15Lecture 15
• Sequencing of the human genome, • Advances in robotics• Advances in computing • Advances in imaging technologies Microarray and
Protenomics Technology
(1) The classification and identification of tumor classes (2) Gene discovery, (3) Determining mechanisms of drug action, and (4) Predicting drug response
Ahmed GroupAhmed GroupLecture 15Lecture 15
Ahmed GroupAhmed GroupLecture 15Lecture 15
• Cancer as a Genetic Disease• Oncogenes• Tumor suppressor genes• Telomeric changes in cancer• Epigenetic changes in cancer: e.g. hypermethylation• Multi-step nature of carcinogenesis• Repair genes in carcinogenesis• The processes of metastasis• Molecular profiling and staging of cancer: Gene
expression profiling and proteomics• Signaling abnormalities in cancer: Effects of signaling abnormalities on radiation responses• Prognostic significance of tumor characteristics• Therapeutic targets and strategies for intervention• Monoclonals, small molecule inhibitors, gene therapy
Cancer
Ahmed GroupAhmed GroupLecture 15Lecture 15
Cell Cycle Regulation
The current concept of the cycle and its regulation by protein kinases, activated by cyclins.
Ahmed GroupAhmed GroupLecture 15Lecture 15
Progression through the cell cycle from one phase to the next is governed by protein kinases, activated by cyclins. In mammals, cyclins A through H have been described: each cyclin protein is synthesized at a discrete phase of the cell cycle. Cyclin levels oscillate with phase of cycle, as shown schematically in this figure
Ahmed GroupAhmed GroupLecture 15Lecture 15
Signal Transduction Pathways
Ionizing radiation can activate both nuclear and membrane-cytoplasmic signal transduction pathways. Their interactions are illustrated in the figure, with the dotted lines representing more hypothetical or controversial effects. The major outcomes of the activation of these pathways are listed in the box on the righthand side of the figure.
Ahmed GroupAhmed GroupLecture 15Lecture 15
Ras mediates its effect on cellular proliferation, at least in partr, by the activation of a cascade of kinases. Ras is a GDP/GTP-regulated binary switch that resides at the inner surface of the plasma membrane and acts to relay extracellular ligand-stimulated signals to cytoplasmic signaling cascades. A linear pathway in which ras functions downstream of receptor tyrosine kinases and upstream of cascade of serine-threonine kinases provides a complete link between the cell surface and the nucleus. Activated ERKs can translocate into the nucleus to phosphorylate and activate transcription factors, such as Elk-1, Activated ERKs also phosphorylate substrates in the cytoplasm, including the Mnk kinase, and thus contribute to translation initiation of mRNAs with structured 5’ – untranslated regions. This is an oversimplified illustration, because there are at least three signaling pathways that lie downstream of ras.
Ahmed GroupAhmed GroupLecture 15Lecture 15
Illustrating the protein kinase C pathway, which processes extracellular signals and transmits tham to the nucleus. Extracellular growth factors (such as PDF) activate a receptor, which in turn activates a G protein that in turn activates the phopholipase C. In less than a second, the enzyme cleaves PIP2 to genrate two products, inositol triphosphate and diacylglycerol. IP3 is a as the endoplasmic reticulum. The enzyme activated by diacylglycerol is protein kinase C, called such because it is Ca2+ dependent. Protein kinase C phosphorylates specific serine and threonine residues on cellular proteins in addition to activating the plasma membrane Na+H+ exchanger that controls intracellular pH. Also, the calcium enters the nucleus and activates the transcription of growth-regulating genes, such as myc and fos.
Ahmed GroupAhmed GroupLecture 15Lecture 15
The role of p53 in transduction of the signal from radiation damage. The transcriptional activity of p53 is modulated in response to DNA damage by the activity of a number of kinases including ATM and DNApk), as well as by protein : protein interactions, resulting in either cell-cycle arrest or apoptosis.
Ahmed GroupAhmed GroupLecture 15Lecture 15
Ahmed GroupAhmed GroupLecture 15Lecture 15
ATM ATM
ATMP
ATM
CHK2
PATM Nbs1 P
ATMPBrca1
P
P
ATMP
p53P
Bax Cell Death
p21 waf1/cip1G1 Arrest
DNA Repair
Ionizing radiation Chromatin
changes
ReactiveOxygenSpecies
EGR-1
Ras AKT/PI3-K
NFB
Bcl-2
TNF-
MDR1
Chemo-Resistance
SurvivalProliferation
Caspaseactivation
Autophosphorylation
Substratephosphorylation
PFocus Formation
Radiation induced signaling response: wild type p53 background
Ahmed GroupAhmed GroupLecture 15Lecture 15
ATM ATM
ATMP
ATMP
Bax
p21 waf1/cip1
DNA Repair
Ionizing radiation Chromatin
changes
ReactiveOxygenSpecies
Mutant p53
Autophosphorylation
Substratephosphorylation
Ras AKT/PI3-K
NFB
Bcl-2
TNF-
MDR1
Chemo-Resistance
SurvivalProliferation
Induced RadiationResistance
Focus Formation
Radiation induced signaling response: mutant p53 background
ATM Nbs1 P
ATMPBrca1
P
P
Ahmed GroupAhmed GroupLecture 15Lecture 15
Grb2
SOSRas
Raf
MEK1/2
ERK1/2
ERK1/2
ERK1/2
ERK1/2
p90rsk
p90rsk
mTOR
AKT/pKB
CREB
c-FosSRF
c-Jun
STAT1/3ELK-1 Ets
PI3K
4E-BP1 p70S6K
PKC
TPAPlasma Membrane
Cytoplasm
Nucleus
Growth factor
Receptor (ex.: EGFR)Growth Factor
(ex.: EGF)
Growthdifferentiation
Survival
MAPK
pp
NFB
NFB
Other cell survival pathways that may affect radiation sensitivity
Ionizing
radiation
Ahmed GroupAhmed GroupLecture 15Lecture 15
Effect of radiation on DU-145 transfectants overexpressing EGR-1 or dominant-negative
mutant of EGR-1
BB
BB
BB
JJ
JJ
JJ
H
HH
HH
H
0.01
0.1
1
0 1 2 3 4 5 6Dose (Gy)
B DU-145/Vector J DU-145/CMV-WT1-EGR1H DU-145/CMV-EGR1DU-145/VectorSF2 : 0.609D0 : 400 cGy
DU-145/CMV-WT1-EGR1SF2 : 0.66D0 : 509 cGy
DU-145/CMV-EGR1SF2 : 0.34D0 : 164 cGy
Ahmed GroupAhmed GroupLecture 15Lecture 15
Ionizing Radiation Induces EGR-1 Protein Which Transactivates via the GC –rich Binding
site in Egr-1+/- and Egr-1 +/+ MEF Cells.
UT 15 m 30 m 1h 3h 6h
UT 15 m 30 m 1h 3h 6h
EGR-1
β-actin
-1EGR
β-actin
5 Gy
5 Gy
-1Egr + / -
-1Egr - / -
Western blot analysisEgr-1 - / - Egr-1 + / -
EBS-CATRADIATIONCMV-EGR-1
+ ++- -+
- + -
+-
-
+-
+
++
-
EBS-CATIRCMV-EGR-1
++-+
+-- +-
Egr-1 + / +
PERCENTCONVERSION 5.3 28.6 10
PERCENTCONVERSION 0 0 58.7 1.8 14 56.6
EBS-CAT reporter assay
Ahmed GroupAhmed GroupLecture 15Lecture 15
Ionizing Radiation Caused Enhanced Cell Death in Egr-1+/- Cells
Untreated 5 Gy (24 hours)
0
10
20
30
Egr-1 (+/-)
Egr-1 (-/-)
TUNEL staining
Gate %GatedR1 18.74R2 9.29R3 18.31R4 14.49R5 2.38
MC540
Ho342
MC540
Ho342
Gate %GatedR1 20.08R2 11.57R3 13.99R4 11.77R5 1.74
Untreated
5 Gy (48 hours)
Egr-1- / - MEFsEgr-1+ / - MEFs
R5
R4R3
R2R1
R5R4R3
R2R1
MC540
Ho342
Untreated
5 Gy (48 hours)
MC540
Ho342
Gate %GatedR1 19.14R2 11.08R3 24.11R4 24.67R5 11.16
Gate %GatedR1 3.42R2 1.27R3 41.88R4 31.75R5 13.95
R5
R4
R3
R2R1
R5
R4
R3
R2R1
MC540 and Hoechst (flow cytometry)
Ahmed GroupAhmed GroupLecture 15Lecture 15
Ionizing Radiation Causes down-regulation of p53 Protein in Egr-1-/- MEF Cells.
Western blot analysis
Ahmed GroupAhmed GroupLecture 15Lecture 15
Transfection of CMV-EGR-1 in Egr-1-/- Cells Lead to Restoration of Sensitivity to
Radiation-Induced Apoptosis.
UT 1h 3h 6h 12h UT 1h 3h 6h 12h
5Gy 5Gy
Egr-1-/-/CMV.EGR1 Egr-1-/-/Vector
p53
β-actin
Western blot analysis
UT 5 Gy (24h) 5 Gy (48h)0
10
20
30
40Egr1-/- (Vector)Egr1-/-(CMV.EGR1))
TUNEL staining
Egr-1 +/- Egr-1 -/-0
10
20
30
40
50
60
Untreated5 Gy
p53-CAT reporter assay
Ahmed GroupAhmed GroupLecture 15Lecture 15
B
J
J
JJ
J
J
J
H
H
H H
H
HH
0.001
0.01
0.1
1
0 1 2 3 4 5 6
Dose (Gy)
SCC-61 (Radiation alone)
J SCC-61(Radiation + Paclitaxel-0.5nM)
H SCC-61(Radiation + Paclitaxel-1nM)
Effects of Radiation alone versus combination of Paclitaxel + Radiation in SCC-61 and SQ-20B cells
C
J
J J
JJ
JJ
H
H
HH
HH
H
0.001
0.01
0.1
1
0 1 2 3 4 5 6
Dose (Gy)
SQ-20B (Radiation alone)
J SQ-20B (Radiation + Paclitaxel-0.5nM)
H SQ-20B (Radiation + Paclitaxel-1nM)
Ahmed GroupAhmed GroupLecture 15Lecture 15
A BHCT-116 HT-29
p53p53 p21waf1/cip1p21waf1/cip1
COLORECTAL CANCER CELL LINES
UT 1h 3h 6h
5 Gy
UT 1h 3h 6h
5 Gy
p53
p21waf1/cip1
β-actin
HCT-116 HT-29
Ahmed GroupAhmed GroupLecture 15Lecture 15
Ahmed GroupAhmed GroupLecture 15Lecture 15
• Cancer as a Genetic Disease• Oncogenes• Tumor suppressor genes• Telomeric changes in cancer• Epigenetic changes in cancer: e.g. hypermethylation• Multi-step nature of carcinogenesis• Repair genes in carcinogenesis• The processes of metastasis• Molecular profiling and staging of cancer: Gene
expression profiling and proteomics• Signaling abnormalities in cancer: Effects of signaling abnormalities on radiation responses• Prognostic significance of tumor characteristics• Therapeutic targets and strategies for intervention• Monoclonals, small molecule inhibitors, gene therapy
Cancer
Ahmed GroupAhmed GroupLecture 15Lecture 15
Breast Cancer
• Markers of tumor proliferation• Steroid hormone receptors• Factors of epidermal cell growth• Plasminogen activators and inhibitors• Factors influencing angiogenesis and apoptosis• Genome characteristics are considered • Ki-67, ER, PR and Her-2/neu recommended for
clinical use.
Ahmed GroupAhmed GroupLecture 15Lecture 15
• Cancer as a Genetic Disease• Oncogenes• Tumor suppressor genes• Telomeric changes in cancer• Epigenetic changes in cancer: e.g. hypermethylation• Multi-step nature of carcinogenesis• Repair genes in carcinogenesis• The processes of metastasis• Molecular profiling and staging of cancer: Gene
expression profiling and proteomics• Signaling abnormalities in cancer: Effects of signaling abnormalities on radiation responses• Prognostic significance of tumor characteristics• Therapeutic targets and strategies for intervention• Monoclonals, small molecule inhibitors, gene therapy
Cancer
Ahmed GroupAhmed GroupLecture 15Lecture 15
Therapeutic targets and strategies for intervention
Problems with traditional cancer treatment regimens:
• nonselective• cytotoxicity in normal as well as in malignant cells• often not well tolerated
In developing novel anticancer agents, the goal is to target specific molecular lesions within tumor cells, leading to improved cure rates and reducing cytotoxicity in normal cells. Advances in the understanding of tumor pathobiology and molecular biology have allowed the development of targeted therapies.
Ahmed GroupAhmed GroupLecture 15Lecture 15Copyright ©2004 AlphaMed Press
The HER family of receptors is the target of several targeted therapies for breast cancer
Esteva, F. J. Oncologist 2004;9:4-9
The human epidermal growth factor receptor (HER-2, ErbB-2) is overexpressed in 20-25% of invasivebreast cancers. It is considered an important therapeutic target, and several types of moleculartherapies have been developed to target the HER family of receptors.
Ahmed GroupAhmed GroupLecture 15Lecture 15
Therapeutic agent Molecular weight (Daltons)
Tyrosine kinase inhibitor (e.g., gefitinib, erlotinib) ~400Peptide vaccine ~1,000Monoclonal antibody (e.g., trastuzumab, cetuximab) ~150,000
Size comparison of molecularly targeted therapies
The molecular wiegth of these types of therapies ranges from 400 daltons to approximately 150,000, which has implications in terms oftumor penetration
Ahmed GroupAhmed GroupLecture 15Lecture 15
Example: Humanized anti-ErbB monoclonal antibodies in development for the treatment of various types of cancers
Antibody Specificity Selected tumor types Development phase
Trastuzumab (Herceptin®; Genentech, Inc.;South San Francisco, CA) HER-2 (ErbB-2) HER-2+ metastatic breast Approved
Cetuximab (Erbitux®;ImClone Systems, Inc.; EGFR (ErbB-1) Colorectal, NSCLC, IIINew York, NY) pancreatic, breast, HNSCC
ABX-EGF (Amgen;Thousand Oaks, CA) NSCLC, EGFR (ErbB-1) NSCLC, olorectal, prostate, II
renal, HNSCC EMD 72000 (EMD Pharma;Durham, NC) EGFR (ErbB-1) NSCLC, colorectal, ovarian, II
HNSCCPertuzumab (OmnitargTM; HER-2 (ErbB-2), Prostate, ovarian, breast, NSCLC I/IIGenentech, Inc. (ligand-dependent signaling)
Abbreviations: HNSCC = head and neck squamous cell carcinoma; NSCLC = non-small cell lung cancer
Monoclonal antibodies
Ahmed GroupAhmed GroupLecture 15Lecture 15
Example: HER tyrosine kinase (TK) inhibitors
Inhibitor Specificity Selected tumor types Development phase
Gefitinib (Iressa®; Astra ErbB-1 TK Locally advanced or metastatic NSCLC, Approved Zeneca; Wilmington, DE) head and neck, breast, prostate,
ovarian ,glioma, pancreatic, colorectal
Erlotinib (TarcevaTM; ErbB-1 TK NSCLC, head & neck, breast, ovarian, IIIGenentech, Inc.; CA) prostate, pancreatic, colorectal, glioma
EKB-569 (Wyeth-Ayerst ErbB-1/2 TK NSCLC, breast, other ErbB-dysregulated I/IILaboratories, Inc.; PA) solid tumors
CI-1033 (Pfizer Inc.; CT) ErbB-1 to –4 NSCLC, breast, other ErbB-dysregulated I/II TK solid tumors
Lapatinib(GlaxoSmithKline; NC) ErbB-1/2 TK ErbB-dysregulated solid tumors II
Abbreviation: NSCLC = non-small cell lung cancer
Small molecules
Ahmed GroupAhmed GroupLecture 15Lecture 15
Radiolabeled Immunoglobulins
• Human antibodies attached to a radioactive isotope
• Purpose is to deliver the radioisotope to the tumor using an antibody which is specific to the tumor
Ahmed GroupAhmed GroupLecture 15Lecture 15
Ahmed GroupAhmed GroupLecture 15Lecture 15
Small molecule inhibitors
Historically, certain classes of molecules have been particularly amenable to the modulation of their activity by small molecule drugs. These classes include receptors and enzyme.
Receptor Tyrosine KinasesA family of proteins collectively referred to as receptor tyrosine kinases (RTKs) provides an attractive group of new molecular targets for cancer therapy. The role of some of these targets in the pathology of cancer cells is well established, and much progress has recently been made in the identification of small-molecule drugs directed against representatives of this class of receptors. Some of these molecules were identified at OSI, like TarcevaTM, which targets the Epidermal Growth Factor Receptor (HER1/EGFR), and CP-724,714 and CP-547,632, both small molecule inhibitors that target the receptor for the Vascular Endothelium Growth Factor (VEGF) (included in angiogenesis) and HER-2/neu, a related protein to HER1/EGFR that is particularly important in breast cancer. These are currently undergoing clinical evaluation (Tarceva™ in partnership with Genentech and Roche, and VEGF inhibitor and HER2/neu inhibitor trials conducted by Pfizer). Several other RTKs are also implicated in various aspects of cancer biology. These RTKs might provide more targets for small-molecule drug discovery and are the subject of active research.
Ahmed GroupAhmed GroupLecture 15Lecture 15
Regulatory Enzymes
Another class of proteins particularly amenable to small-molecule drug discovery are regulatory enzymes. There are many examples of small molecule drugs that disrupt transfer of small chemical groups in reactions involving enzymes. Different enzyme classes catalyze these group transfer reactions: kinases, methyltransferases, acetyltransferases, deacetylases and phosphatases, to name a few. These enzymes can act to modify proteins in post-translational modification events that regulate key cellular processes necessary for continued cell division and growth. Broad-spectrum inhibition of cGMP phosphodiesterases has been shown to lead to elevated in cGMP levels and sustained activation of Protein-Kinase G (PKG). This in turn directly phosphorylates MEKK1, leading to activation of the N-terminal cJun Kinase (JNK-1) pathway, a known pro-apoptotic signaling pathway. Kinases catalyze the transfer of a phosphate group to proteins.
Small molecule inhibitors
Ahmed GroupAhmed GroupLecture 15Lecture 15
Deregulated Signaling Pathways in Cancer
Within the processes of proliferation or apoptosis examples are three key signaling axes (see next slide), namely the Ras-Raf-Mek-Erk axis (pathway 1); the PI-3K-PDK-PKB axis (pathway 2) and the PKG-MEKK1-JNK1 axis (pathway 3). These three pathways are thought to be critical in driving either cancer cell proliferation (EGFR or c-kit via pathway 1) or in protecting cancer cells from undergoing apoptosis (IGF-1R or PKB via pathway 2, and PDEs and PKG via pathway 3). Importantly these signaling pathways also form a framework that allows combination approaches to be designed and evaluated such that OSI can leverage the maximal therapeutic impact of novel targeted therapies (e.g. Tarceva, OSI-461).
Potential therapeutic targets
Ahmed GroupAhmed GroupLecture 15Lecture 15
Proteins such as PDK-1 and PKB as potential targets, as they are critical downstream elements of the IGF-1R signal transduction path essential in suppression of apoptosis.One example of our approach to inhibit cellular proliferation is via inhibition of the Epidermal Growth Factor Receptor (EGFR). This receptor is over-expressed or mutated in many human cancers, contributing critically to their aberrant signaling and the development of tumors. Our lead small-molecule inhibitor of the HER1/EGFR, TarcevaTM, received approval in November 2004.attempts to modulate apoptosis, is through activation of Protein Kinase G (PKG) signaling. Broad-spectrum inhibition of cGMP phosphodiesterases has been shown to lead to elevated of cGMP levels and sustained activation of PKG. This in turn directly phosphorylates MEKK1, leading to activation of the N-terminal cJun kinase (JNK-1) pathway and apoptosis of cancer cells.
Ahmed GroupAhmed GroupLecture 15Lecture 15
Cancer gene-therapy is the transfer of nucleic acids into tumor/normal cells to eliminate or reduce tumor burden by:
•Direct cell-killing
•Immunomodulation
•Correcting genetic errors to reverse malignant state
Cancer gene therapy
Ahmed GroupAhmed GroupLecture 15Lecture 15
In 1990: First experiment in Gene Therapy to treat Adenosine Deaminase Deficiency
By the end of 1993: 45 trials by US
Recombinant DNA Advisory Committee
30 to treat cancer
Ahmed GroupAhmed GroupLecture 15Lecture 15
TechnologiesGene therapy for the treatment of
cancer has a wide variety of potential uses. There are several
potential strategies for gene therapy in the treatment of
cancer.
Ahmed GroupAhmed GroupLecture 15Lecture 15
Germinal Gene Therapy
Somatic Gene Therapy
Ex-vivo
In-vivo
TWO TYPES OF GENE THERAPY(ON THE TISSUE -SPECIFIC)
Ahmed GroupAhmed GroupLecture 15Lecture 15
Strategies of Gene Therapy for Cancer
• Enhancing the immunogenicity of the tumor, for example: introducing genes that encode foreign antigens.
• Enhancing immune cells to increase anti-tumor activity, for example: introducing genes that encode cytokines.
• Inserting a "sensitivity" or suicide' gene into the tumor, for example: introducing the gene that encodes HSV-tk.
Ahmed GroupAhmed GroupLecture 15Lecture 15
Strategies of Gene Therapy for Cancer
• Blocking the expression of oncogenes, for example: introducing the gene that encodes antisense K-RAS message.
• Inserting a wild-type tumor suppressor gene, for example: p53 or the gene involved in Wilms' tumor.
• Protecting stem cells from the toxic effects of chemotherapy, for example: introducing the gene that confers MDR-1.
Ahmed GroupAhmed GroupLecture 15Lecture 15
Strategies of Gene Therapy for Cancer
• Blocking the mechanisms by which tumors evade immunological destruction, for example: introducing the gene that encodes antisense IGF-l message.
• Killing tumor cells by inserting toxin genes under the control of a tumor-specific promoter, for example: gene that encodes diphtheria A chain.
Ahmed GroupAhmed GroupLecture 15Lecture 15
Ex – Vivo Gene Transfer
Tumor
Induction of significant systemic immune response
Kill tumor cells
No recurrence
Tumor cells
In tissue culture
Re-inject
Transfer with gene
ImmunostimulationIL-1b IL-2IL-4 IL-6TNF- GM-CSFV-interferon
Ahmed GroupAhmed GroupLecture 15Lecture 15
Tumor Tumor cells Irradiate
FibroblastIrradiated tumors & Fibroblast containing the gene
Transfectwith viral vectors containing genes such as IL-2, TNF, KM-CSF or
Block IRF-1 Expressions
RE-INJECT
Fibroblast
Ex – Vivo Gene Transfer
Ahmed GroupAhmed GroupLecture 15Lecture 15
Anti-sense approach
Ahmed GroupAhmed GroupLecture 15Lecture 15
HSV-skSuicide genein viral vector
Toxic
Ganciclovir
P
P
P
Not toxic
Not toxicGanciclovir
given systematically
INSERTION OF SUCIDE GENE
Ahmed GroupAhmed GroupLecture 15Lecture 15
INSERTION OF A SENSITIVITY GENE
Anti-Herpes DrugGanciclovir (GCV)
PhosphorylatesGCV-MP
ThymidineKinase (TK)
GCV-TP
Inhibition of DNA Polymerases
Cell Death
Ahmed GroupAhmed GroupLecture 15Lecture 15
TK gene & Herpes simplex virus (on vector) [HSVtk]
Infect The Tumor
Patient Is Given GCV
GCV Kills Selectively
The tumor cells carrying HSVtk
gene and also cause bystander effect (kills adjacent cells too)
INSERTION OF A SENSITIVITY GENE
Ahmed GroupAhmed GroupLecture 15Lecture 15
Another Example5 –Fluorocytosine
5 – Fluorouracil (Cytotoxic)
• Cytosine Deaminase
Cell Death
Ahmed GroupAhmed GroupLecture 15Lecture 15
Cholangiocarcinoma
AdCD gene therapy + radiation +FC
Ahmed GroupAhmed GroupLecture 15Lecture 15
Ahmed GroupAhmed GroupLecture 15Lecture 15
Table 1: Schedule of delivery of viral vector (Ad. CMV.CD) at a dose of 108
plaque forming units (PFU/injection, 5-FC at a dose of 800mg/kg body weight, and x-irradiation (XRT) at a dose of 5 Gy/day.
Ahmed GroupAhmed GroupLecture 15Lecture 15
• Gene coding for Cytosine Deaminase has been used in animal Gene Therapy Trials
• Some studies have used in combination with Radiation to produce enhanced killing since 5-FU is a Radiosensitizer
Ahmed GroupAhmed GroupLecture 15Lecture 15
Restoration of G1 checkpointAdp53 therapy
Nasal Vestibule
Radio sensitive human fibroblast
Ahmed GroupAhmed GroupLecture 15Lecture 15
Induction of apoptosis. The percentage of apoptotic cells was determined by cytometry in a JSQ-3 population, 72 hours after exposure to 2 Gy of radiation.
Ahmed GroupAhmed GroupLecture 15Lecture 15
Adp53 therapyAdp53 therapy
Ahmed GroupAhmed GroupLecture 15Lecture 15
Breast Tumor Isolate tumor cells
Isolate MDR-1 gene
Clone in viral vector
Infect MDR-1 HSC2
Re-Inject
PheresisStem cells
Treat with high-doses of Taxol.
PROTECTION OF HEMATOPOIETICSTEM CELLS (HSC2)
Ahmed GroupAhmed GroupLecture 15Lecture 15
Radiation Inducible Gene Therapy
Physics of Radiation Targeting
Molecular Aspectsof Gene Therapy
Radiation InduciblePromoter
CytotoxicAgent
Egr-1Promoter-enhancer
TNF-alphaalpha
+
+
+
Adenovirus
Ahmed GroupAhmed GroupLecture 15Lecture 15
Tumor CellInduces
TNF-alpha GeneExpression
Cells killed orradiosensitizedby TNF-alpha
Adenoviruscontaining
EGR-TNF-alpha
IntratumorInjection
X-rays
Ahmed GroupAhmed GroupLecture 15Lecture 15
RADIO-GENE THERAPY
Fig. 1 Reduction of SQ-20B tumour volumes following combined treatment. SQ-20B xenografts were injected with 1x108 PFU of Ad5 (null virus) or 2 x 108 PFU of Ad.Egr-TNF (twice a week for two weeks). Control tumours were not injected. Tumours were irradiated (5 Gy per day, 4 days per week) to a total dose of 40 or 50 Gy. A, Volumes of xenografts are shown following treatment with: Control (untreated); radiation alone at 50 Gy; Ad.Egr-TNF alone; Ad.Egr-TNF and 50 Gy. Data are calculated as the percent of original (day 0) tumour volume and graphed as fractional tumour volume+ s.e.m. b, Volumes of xenografts are shown following treatment with: 40Gy; Ad5 (null virus); Ad5 (null virus) + 40Gy.
Replace tumor deficient
A5 Egr-TNF
Ahmed GroupAhmed GroupLecture 15Lecture 15
Fig. 2: Treatment effects on large versus small tumors. A, Mean volumes of large (160 mm3) and small xenografts after treatment with radiation alone. The mean of large tumours at day 0 was 234 + 25 mm3 and the mean of small tumours at day 0 was 114 + 6 mm3 . B, Mean volumes of large (.160 mm3 ) and small xenografts after treatment with Ad.Egr-TNF and radiation. The mean of large tumours at day 0 was 218 + 14 mm3 and the mean of small tumours was 96 + 12mm3.